RT Journal Article
SR Electronic
A1 Hoyle, Brian
T1 Nintedanib is Safe and Effective in Patients with IPF: Results of the INPULSIS Trials
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 11
SP 14
OP 16
DO 10.1177/155989771411008
UL http://mdc.sagepub.com/content/14/11/14.abstract
AB Nintedanib, a tyrosine kinase inhibitor that targets fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor, was shown to lessen the decline in lung function and decrease acute exacerbations in patients with idiopathic pulmonary fibrosis (IPF) in the Phase 2 TOMORROW study [Richeldi L et al. N Engl J Med 2011]. This article presents the primary results for two 52-week Phase 3 randomized, placebo-controlled trials (Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients [INPULSIS] I and II) [Richeldi L et al. N Engl J Med 2014].